Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.72 |
| ▸ | RAB9A | P51151 | 6/20 | 0.72 |
| ▸ | NPC1 | O15118 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.72 |
| ▸ | F10 | P00742 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | PHGDH | O43175 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2414416 | 0.87 | PHGDH (0.70) | SMN1; SMN2RAB9ANPC1MAPTMAPK1 | |
| SCHEMBL27847056 | 0.84 | PHGDH (0.74) | SMN1; SMN2RAB9ANPC1MAPTMAPK1 | |
| SCHEMBL641989 | 0.84 | PHGDH (0.77) | SMN1; SMN2RAB9ANPC1MAPTMAPK1 | |
| SCHEMBL6958604 | 0.82 | PHGDH (0.76) | SMN1; SMN2RAB9ANPC1MAPTKMT2A | |
| SCHEMBL10376329 | 0.82 | PHGDH (0.70) | SMN1; SMN2RAB9ANPC1MAPTMAPK1 | |
| SCHEMBL6169544 | 0.82 | NPC1 (0.78) | SMN1; SMN2RAB9ANPC1MAPTMAPK1 | |
| SCHEMBL8293254 | 0.82 | MAPT (0.59) | SMN1; SMN2RAB9ANPC1MAPTMAPK1 | |
| SCHEMBL7278132 | 0.81 | PHGDH (0.68) | SMN1; SMN2RAB9ANPC1MAPTMAPK1 | |
| SCHEMBL3821744 | 0.81 | F10 (0.93) | SMN1; SMN2RAB9ANPC1F10KMT2A | |
| SCHEMBL27847196 | 0.80 | RAB9A (0.60) | SMN1; SMN2RAB9ANPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1007037-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2004-10-06 | — | — | EP | disclosed |
| US-6677369-B2 | CARBOXIMIDAMIDE DERIVATIVE ANTICOAGULANTS INHIBIT FACTOR XA | ELI LILLY AND COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030195223-A1 | An anticoagulant, blood inhibitor of factor Xa, a N1-amidinebenzoyl- N2-benzoyl-1,2-benzenediamine derivatives; chemical intermediates | BEIGHT DOUGLAS WADE (US) | 2003-10-16 | — | — | US | disclosed |
| US-6417200-B1 | BLOOD COAGULATION FACTOR XA IN MAMMALS | ELI LILLY AND COMPANY | 2002-07-09 | — | — | US | disclosed |
| EP-1007037-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999000127-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195223-A1 | An anticoagulant, blood inhibitor of factor Xa, a N1-amidinebenzoyl- N2-benzoyl-1,2-benzenediamine derivatives; chemical intermediates | F12, F11, F2 | SMN1; SMN2 3164/4885RAB9A 2402/4885NPC1 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.